EODData

MEMBERSHIP REGISTER LOG IN

ASX, MSB: Mesoblast Ltd.

07 Nov 2025
LAST:

2.220

CHANGE:
 0.07		OPEN:
2.270		HIGH:
2.290		ASK:
2.390		VOLUME:
3.45M
CHG(%):
3.06		PREV:
2.290		LOW:
2.205		BID:
2.360		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
07 Nov 252.2702.2902.2052.2203.45M
06 Nov 252.4202.4302.2702.2904.3M
05 Nov 252.4102.4652.3702.4103.17M
04 Nov 252.4602.4602.3952.4102.4M
03 Nov 252.5402.5502.4502.4802.78M
31 Oct 252.5102.5402.4802.5102.56M
30 Oct 252.5102.5302.4802.5102.14M
29 Oct 252.5802.5802.5102.5101.89M
28 Oct 252.5902.5902.4902.5602.82M
27 Oct 252.6102.6202.5402.5603.15M

COMPANY PROFILE

Name:Mesoblast Ltd.
About:Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure; MPC-25-IC for the treatment or prevention of acute myocardial infarction; and Ryoncil for the treatment of pediatric SR-aGVHD; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.
Sector:Healthcare
Industry:Biotechnology
Address:55 Collins Street, Melbourne, VIC, Australia, 3000
Website:https://www.mesoblast.com
ISIN:AU000000MSB8
FIGI:BBG000CS0B18

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:0.11 
Forward P/E:-4.83 
PEG Ratio:-4.83 
Price to Sales:183.88 
Price to Book:5.28 
Profit Margin:0.70 
Operating Margin:-3.02 
Return on Assets:-0.05 
Return on Equity:-0.19 
EPS Ratio:-0.13 
Revenue:26.26M 
Shares:1.281B 
Market Cap:2.844B 

TECHNICAL INDICATORS

MA5:2.366.4%
MA10:2.4510.2%
MA20:2.5816.3%
MA50:2.4711.3%
MA100:2.293.3%
MA200:2.191.4%
RSI14:26.60 
WPR14:-100.00 
MTM14:-0.69
ROC14:-0.24 
ATR:0.11 
Week High:2.5514.9%
Week Low:2.210.7%
Month High:3.0738.3%
Month Low:2.211.4%
Year High:3.3751.8%
Year Low:1.3366.9%
Volatility:52.38